AAIC Abstract and Session Submission Guidelines
Abstract submission for AAIC 2024 opens in December 2023.
AAIC offers unparalleled exposure for your research across the field. Submit your abstract or session proposal for the opportunity to feature your work among 5,600 abstracts submitted on the latest dementia research. Highlight your work in front of dementia researchers from around the globe and bring key opinion leaders together to impact the future of the field. Opportunities to present in person and online will be available.
On This Page:
- Submit an Abstract to AAIC
- Submit a Session Proposal to AAIC
- Submit an Abstract to a Preconference
- Themes, Topics and Subtopics
Submit an Abstract to AAIC
Individual abstract submissions provide an opportunity for presenting authors to share and discuss designs, data and analysis with AAIC attendees. The following abstract types are eligible for submission to AAIC:
- Original: The abstract primarily contains new designs, data or analyses that will not be published or presented prior to AAIC 2024.
- Update: The abstract provides updates on designs, data or analyses that have been published or presented prior to AAIC 2024.
- Encore: The abstract will be published verbatim prior to AAIC 2024. Please note, encore abstracts will not be published in Alzheimer’s & Dementia.
Individual abstracts can be submitted for consideration for an oral and/or a poster presentation, with original, update, and encore abstracts all eligible for oral or poster presentations. The presenting author of an abstract may attend either in-person or virtually for either oral or poster presentations.
Submit a Session Proposal to AAIC
It is also possible to organize and submit a session proposal and help shape the program at AAIC 2024.
Featured Research Sessions (FRS) debut and discuss innovative and impactful research findings, drawing together multiple studies that share a common focus.
- FRS are 75 minutes in length, and comprise 2 chairs and 4-6 presenters, with each presenter submitting an structured abstract.
- If an FRS is not accepted, abstracts that receive an appropriate average score are automatically considered by the SPC for an oral or poster presentation.
Perspectives Sessions provide both an expert review of recent advances and propose a road-map for the future, incorporating multiple viewpoints to stimulate original discussion and debate. Perspectives sessions should interest and engage the core audience of the field being discussed, and also offer an entryway for attendees from other fields.
- Perspectives Sessions are 75 minutes in length, and comprise 2 chairs and 4-6 presenters, with each presenter submitting an unstructured abstract that may or may not contain new findings, data, or analyses.
- If a Perspectives Session is not accepted, abstracts are not transferred to be considered for an oral or poster presentation.
For both Featured Research and Perspectives Sessions, each chair and presenter may attend either in-person or virtually, with any combination of in-person and virtual attendance permitted. Unless the topic demands otherwise, the session should be diverse in terms of the demographics of presenters.
Submit an Abstract to a Preconference
Abstracts submitted to AAIC can also be submitted to the Alzheimer’s Imaging Consortium (AIC) or the Technology and Dementia preconferences as part of the submission process. Please note, the AIC and the Technology and Dementia preconferences take place in-person only and require an additional registration fee to AAIC.
Please submit the abstract to AAIC, and select “I would also like to submit this abstract to a preconference. I understand that preconferences take place in-person only and require an additional registration fee to AAIC.” during the submission process. Abstracts will be considered for both AAIC and the preconference.
Themes, Topics and Subtopics
Selection of a theme, topic and subtopic for the abstract allows submitters to "self-identify" the area in which the abstract best fits. This identification is the first step in sorting abstracts for the Scientific Program Committee, who will take this identification into consideration and group related abstracts with similar topics into the same session. Selection of a primary theme, topic and subtopic is required.
Accepted themes:
- Basic Science and Pathogenesis
- Biomarkers
- Clinical Manifestations
- Dementia Care and Psychosocial Factors
- Dementia Care Practice
- Drug Development
- Public Health
Theme: Basic Science and Pathogenesis
- Topic: Genetics
- Blood-borne markers of CNS disease
- Endophenotypes
- Epigenetics
- Genetic factors of Alzheimer’s disease
- Genetic factors of non-Alzheimer’s disease
- Genetics of cognitive aging
- Genetics of systems biology
- Topic: Human Neuropathology
- Alpha-synuclein
- Amyloid
- Clinico-pathologic correlations
- Etiopathogenesis--links to brain disease
- Imaging-pathologic correlations
- Novel methods
- Other
- Proteinopathies
- Selective vulnerability
- Tau
- Topography of pathology
- Vascular
- Topic: Molecular and Cell Biology
- α-synuclein
- APP/Abeta/Amyloid
- Axonal transport
- Calcium homeostasis
- Cell cycle disruption
- Endosomal-lysosomal dysfunction
- Enzyme activities
- Innate immunity
- Metabolic stress
- Mitochondrial function/energetics
- Neurodegeneration and neuroprotection
- Neuroinflammation
- Other
- Oxidative stress
- Presenilins
- Protein-protein interactions
- Proteostasis
- Receptors
- Signal transduction
- Stem cells, IPS cells
- Systemic immunity
- Synaptic disruption
- Tau
- TDP-43
- Vascular factors
Theme: Biomarkers
- Topic: Biomarkers (non-neuroimaging)
- Differential diagnosis
- Human neuropathology
- Longitudinal change over time
- Method development and/or quality control
- Multi-modal comparisons
- Novel biomarkers
- Plasma/serum/urine biomarkers
- Prognostic utility
- Use in clinical trial design and evaluation
- Topic: Neuroimaging
- Animal imaging
- Differential diagnosis
- Evaluating treatments
- Imaging and genetics
- Multi-modal comparisons
- New imaging methods
- Normal brain aging
- Optimal neuroimaging measures for early detection
- Optimal neuroimaging measures for tracking disease progression
Theme: Clinical Manifestations
- Topic: Neuropsychiatry and Behavioral Neurology
- Assessment/measurement epidemiology of neuropsychiatric/behavioral and psychological symptoms
- Clinical aspects of behavioral neurology and neuropsychiatry
- Dementia
- Mild cognitive impairment/prodromal disease
- Normal cognition/subjective cognitive decline/preclinical disease
- Interventions
- Treatment development and clinical trials for neuropsychiatric symptoms
- Topic: Neuropsychology
- Computerized neuropsychological assessment
- Early detection of cognitive decline with neuropsychological tests
- Measurements of function
- Multicultural issues in assessment of dementia
- Neuropsychological correlates of physiologic markers of cognitive decline/dementia
- Neuropsychological profiles of dementia
- Normal cognitive aging
Theme: Dementia Care and Psychosocial Factors
- Topic: Dementia Care Research (research projects; nonpharmacological)
- Assessment and care planning
- Behavioral interventions
- Community care
- Cross-cultural studies and cultural/linguistic adaptations
- Family/lay caregiving
- Instrument development, program evaluation and translation
- Long-term care
- Therapeutic strategies and interventions
- Use of technologies
- Topic: Psychosocial Factors and Environmental Design
- Environmental design and technology
- Living with dementia and quality of life
- Social networks
Theme: Dementia Care Practice
- Topic: Dementia Care Practice (descriptive)
- Implementation of person-centered care
- Managing dementia-related behaviors
- Other innovative programs and practices
- Supportive and therapeutic environments
- Transition and coordination of services
- Workforce initiatives
Theme: Drug Development
- Topic: Human
- Human trials: Anti-amyloid
- Human trials: Anti-tau
- Human trials: Cognitive enhancement
- Human trials: Inflammation
- Human trials: Nutraceuticals and non-pharmacological interventions
- Human trials: Other
- Human trials: Other behavioral symptoms
- Novel outcomes measures
- Prevention (clinical)
- Trial design
- Topic: Nonhuman
- Lead optimization studies
- Natural products and nutraceuticals
- Nonpharmacological interventions
- Novel screening strategies
- Target identification and validation studies: Amyloid
- Target identification and validation studies: Cognitive enhancement and other behavioral symptoms
- Target identification and validation studies: Inflammation and innate immunity
- Target identification and validation studies: Neuronal and synaptic protection
- Target identification and validation studies: Other
- Target identification and validation studies: Proteostasis
- Target identification and validation studies: Tau
Theme: Public Health
- Topic: Epidemiology
- Innovative methods in aging (i.e. assessment methods, design, recruitment strategies, statistical methods, etc.)
- Prevalence, incidence, and outcomes of MCI and dementia
- Risk and protective factors in MCI and dementia
- Topic: Health Services Research
- Cost-effectiveness of treatment/prevention and diagnosis
- Cost of care
- Policy and plans
- Services
- Topic: Prevention (nonpharmacalogical)
- Cognitive interventions
- Exercise
- Lifestyle factors (e.g., smoking, etc.)
- Multidomain
- Nutrition
- Other
Advance Your Career
Join ISTAART, an inclusive global network of scientists, clinicians and dementia professionals. With newly discounted rates and free memberships for students, it’s easier than ever to become a part of ISTAART.
Security and Privacy Policy | alz.org
We use cookies to improve your experience on this website. Learn about options for managing your personal data in our Privacy Policy.
lg > 992px
md > 768px
sm < 767px
xs
Join the Conversation #AAIC23